BioWorld Asia

Oct. 22, 2008

Sygnis Pulls in $24M in Rights Offering for Stroke Drug Trial

Underlining the value of having big backers in these straitened times, Sygnis Pharma AG unveiled an €18.3 million (US$24.4 million) rights offering that already is fully backed by its two largest shareholders. (BioWorld International) Read More

Companies Doing 'Unimaginable' as Deal-Making Landscape Alters

Researchers Successfully Comb the Genome for Baldness Genes

Basilea Racks Up European Approvals for Alitretinoin

Pfizer, UCB Create New Firm with Help from Public Funding

Immutep to Carry Out Phase I Trial of ImmuFact IMP321 in U.S.

Firms Say Advanced Therapies Still Lack Clear EU Definition

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 22, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...